GEP20227387B - Methods and compositions for treating sleep apnea - Google Patents

Methods and compositions for treating sleep apnea

Info

Publication number
GEP20227387B
GEP20227387B GEAP201815226A GEAP2018015226A GEP20227387B GE P20227387 B GEP20227387 B GE P20227387B GE AP201815226 A GEAP201815226 A GE AP201815226A GE AP2018015226 A GEAP2018015226 A GE AP2018015226A GE P20227387 B GEP20227387 B GE P20227387B
Authority
GE
Georgia
Prior art keywords
compositions
methods
sleep apnea
treating sleep
nri
Prior art date
Application number
GEAP201815226A
Other languages
English (en)
Inventor
Luigi Taranto-Montemurro
Andrew D Wellman
Original Assignee
Brigham & Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63918622&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GEP20227387(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Brigham & Womens Hospital Inc filed Critical Brigham & Womens Hospital Inc
Publication of GEP20227387B publication Critical patent/GEP20227387B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
GEAP201815226A 2017-04-28 2018-04-26 Methods and compositions for treating sleep apnea GEP20227387B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762491504P 2017-04-28 2017-04-28
US201762558814P 2017-09-14 2017-09-14

Publications (1)

Publication Number Publication Date
GEP20227387B true GEP20227387B (en) 2022-06-10

Family

ID=63918622

Family Applications (4)

Application Number Title Priority Date Filing Date
GEAP201815226A GEP20227387B (en) 2017-04-28 2018-04-26 Methods and compositions for treating sleep apnea
GEAP202416602A GEAP202416602A (en) 2017-04-28 2018-04-26 Methods and compositions for treating sleep apnea
GEAP201815757A GEP20247617B (en) 2017-04-28 2018-04-26 Methods and compositions for treating sleep apnea
GEAP201816320A GEP20257788B (en) 2017-04-28 2018-04-26 Methods and compositions for treating sleep apnea

Family Applications After (3)

Application Number Title Priority Date Filing Date
GEAP202416602A GEAP202416602A (en) 2017-04-28 2018-04-26 Methods and compositions for treating sleep apnea
GEAP201815757A GEP20247617B (en) 2017-04-28 2018-04-26 Methods and compositions for treating sleep apnea
GEAP201816320A GEP20257788B (en) 2017-04-28 2018-04-26 Methods and compositions for treating sleep apnea

Country Status (22)

Country Link
US (4) US11123313B2 (enExample)
EP (1) EP3615016A4 (enExample)
JP (3) JP7373997B2 (enExample)
KR (3) KR102682159B1 (enExample)
CN (2) CN110799181A (enExample)
AU (3) AU2018260666B2 (enExample)
BR (1) BR112019022483A2 (enExample)
CA (1) CA3061468A1 (enExample)
CO (1) CO2019013180A2 (enExample)
CR (1) CR20190546A (enExample)
DO (1) DOP2019000274A (enExample)
EC (1) ECSP19084058A (enExample)
GE (4) GEP20227387B (enExample)
MA (1) MA49069A (enExample)
MX (2) MX394941B (enExample)
MY (1) MY200172A (enExample)
NI (1) NI201900110A (enExample)
PH (1) PH12019502427A1 (enExample)
SG (2) SG10202111623TA (enExample)
UA (1) UA127759C2 (enExample)
WO (1) WO2018200775A1 (enExample)
ZA (1) ZA201907158B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110799181A (zh) * 2017-04-28 2020-02-14 布里格姆妇女医院 用于治疗睡眠呼吸暂停的方法和组合物
PT3746126T (pt) * 2018-01-30 2024-10-21 Apnimed Inc Delaware Métodos e composições para o tratamento de apneia do sono ou roncopatia simples
CN108309261B (zh) * 2018-02-11 2020-05-22 西安交通大学 一种猝死预警方法及装置和系统
US20190381056A1 (en) 2018-06-17 2019-12-19 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
US20200147093A1 (en) 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
US11020402B2 (en) 2018-10-15 2021-06-01 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
JP2022506113A (ja) * 2018-10-31 2022-01-17 アプニメッド，インコーポレイテッド（デラウェア） 睡眠時無呼吸を治療するための方法及び組成物
PH12021551850A1 (en) * 2019-02-08 2022-05-11 Brigham & Womens Hospital Inc Methods and compositions for treating sleep apnea
WO2021091902A1 (en) * 2019-11-04 2021-05-14 Apnimed, Inc. (Delaware) Combination pharmacological interventions for multiple mechanisms of obstructive sleep apnea
JP7776442B2 (ja) 2020-05-05 2025-11-26 アプニメッド，インコーポレイテッド（デラウェア） （ｒ）－オキシブチニン塩酸塩の多形形態
CN114159568B (zh) * 2020-09-11 2025-08-01 北京原基华毅生物科技有限公司 Sik抑制剂在制备用于预防和/或治疗睡眠障碍的药物中的应用
RU2757470C1 (ru) * 2020-11-19 2021-10-18 Ренат Рашитович Ахмеров Способ лечения храпа с помощью введения тромбоцитарной аутологичной плазмы
WO2022155162A1 (en) * 2021-01-14 2022-07-21 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea
JP2024508498A (ja) * 2021-03-04 2024-02-27 アプニメッド，インコーポレイテッド（デラウェア） 睡眠時無呼吸の治療における使用のためのレボキセチン及びムスカリン受容体拮抗薬（ｍｒａ）の組み合わせ
EP4322930A1 (en) * 2021-04-16 2024-02-21 Apnimed, Inc. (Delaware) Combination of a norepinephrine reuptake inhibitor and a cannabinoid for use in treating sleep apnea
EP4355333A1 (en) * 2021-06-17 2024-04-24 Apnimed, Inc. (Delaware) Norepinephrine reuptake inhibitors for treating sleep apnea
US20240358709A1 (en) * 2021-08-31 2024-10-31 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea
EP4452242A1 (en) 2021-12-22 2024-10-30 Bayer Aktiengesellschaft Combination of an ?2-adrenoceptor subtype c (alpha-2c) antagonist with a norepinephrine reuptake inhibitor for the treatment of sleep apnea
CN118434414A (zh) 2021-12-22 2024-08-02 拜耳公司 用于治疗睡眠呼吸暂停的α2-肾上腺素受体亚型C（α-2C）拮抗剂与毒蕈碱受体拮抗剂的结合物
KR20240127384A (ko) * 2021-12-22 2024-08-22 바이엘 악티엔게젤샤프트 수면 무호흡의 치료를 위한 task1/3 채널 차단제와 노르에피네프린 재흡수 억제제의 조합물
WO2023219991A1 (en) * 2022-05-13 2023-11-16 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU767877B2 (en) 1999-05-20 2003-11-27 Sepracor, Inc. Methods for treatment of asthma using S-oxybutynin
CN1396829A (zh) * 2000-02-24 2003-02-12 法玛西雅厄普约翰美国公司 新的药物联合形式
WO2006023702A2 (en) * 2004-08-20 2006-03-02 Cypress Bioscience, Inc. Method for treating sleep related breathing disorders with setiptiline
CA2590802A1 (en) * 2004-12-20 2006-06-29 Collegium Pharmaceutical, Inc. Pharmaceutical compositions for sleep disorders
CN103458899A (zh) * 2011-01-28 2013-12-18 辉达斯医学研究所 治疗阻塞性睡眠呼吸暂停的方法
CN110799181A (zh) * 2017-04-28 2020-02-14 布里格姆妇女医院 用于治疗睡眠呼吸暂停的方法和组合物
PT3746126T (pt) * 2018-01-30 2024-10-21 Apnimed Inc Delaware Métodos e composições para o tratamento de apneia do sono ou roncopatia simples

Also Published As

Publication number Publication date
US11123313B2 (en) 2021-09-21
US20210401777A1 (en) 2021-12-30
JP2020517719A (ja) 2020-06-18
MA49069A (fr) 2020-03-04
MY200172A (en) 2023-12-12
EP3615016A4 (en) 2021-02-24
KR20250145704A (ko) 2025-10-13
KR102682159B1 (ko) 2024-07-08
KR20240042261A (ko) 2024-04-01
JP2025169279A (ja) 2025-11-12
ZA201907158B (en) 2021-09-29
CN119185558A (zh) 2024-12-27
AU2025230729A1 (en) 2025-10-02
CR20190546A (es) 2020-04-08
AU2022241471A1 (en) 2022-10-27
SG10202111623TA (en) 2021-12-30
BR112019022483A2 (pt) 2020-05-12
GEAP202416602A (en) 2024-10-10
US20240189261A1 (en) 2024-06-13
AU2018260666B2 (en) 2022-07-21
MX2022010349A (es) 2022-09-19
MX394941B (es) 2025-03-24
JP2023139000A (ja) 2023-10-03
GEP20247617B (en) 2024-04-25
JP7373997B2 (ja) 2023-11-06
US20200054583A1 (en) 2020-02-20
US20240261239A1 (en) 2024-08-08
AU2018260666A1 (en) 2019-11-14
KR20190140019A (ko) 2019-12-18
NZ758564A (en) 2023-12-22
WO2018200775A1 (en) 2018-11-01
MX2019012729A (es) 2019-12-19
ECSP19084058A (es) 2020-01-31
SG11201909973UA (en) 2019-11-28
GEP20257788B (en) 2025-08-25
CO2019013180A2 (es) 2020-02-07
NI201900110A (es) 2020-03-18
DOP2019000274A (es) 2019-12-30
CN110799181A (zh) 2020-02-14
CA3061468A1 (en) 2018-11-01
PH12019502427A1 (en) 2020-10-05
UA127759C2 (uk) 2023-12-27
EP3615016A1 (en) 2020-03-04

Similar Documents

Publication Publication Date Title
GEP20227387B (en) Methods and compositions for treating sleep apnea
IL276247A (en) Methods and materials for the treatment of sleep apnea
MX2017014192A (es) Composiciones y metodos de tratamiento de una enfermedad neurodegenerativa.
TW201713341A (en) Compositions and methods of treating a neurodegenerative disease
MX2025004365A (es) Metodos y composiciones para el tratamiento de la apnea del sue?o
WO2014120936A3 (en) Treatments for depression and other diseases with a low dose agent
MX2015009696A (es) Composiciones estables que comprenden heparinoide, anestesico de accion aguda y regulador de ph.
MX2024013184A (es) Metodos y composiciones para tratar apnea del sue?o
IL281645A (en) Alpha2-adrenoceptor subtype 2 antagonists (ALPHA-2C) for the treatment of sleep apnea
AU2014287427B2 (en) Compositions and methods for treating neuropsychiatric disorders using an endothelin-B receptor agonist
MX370061B (es) Uso de antagonistas del par-1 para prevenir y/o tratar condiciones patologicas funcionales pelviperineales.
EA201992569A1 (ru) Способы и композиции для лечения апноэ во сне
SG11202110423UA (en) Anesthetic composition and method of anesthetizing the eye
HK40059516A (en) Methods and compositions for treating sleep apnea
PT3703818T (pt) Antagonista de il-4r para utilização num método para o tratamento ou prevenção de asma
HK40017009A (en) Methods and compositions for treating sleep apnea
HK1245077A1 (en) Compositions and methods of treating a neurodegenerative disease